MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin-like growth factor 1 (IGF1)/IGF2, HGF/MET and HER2/HER3 have been reported to activate the PI3K/AKT and RAS/RAF/MEK/ERK axis independently of EGFR [172,173].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“The proto-oncogene MET, which enforces hepatocyte growth factor receptor (HGFR, also known as MET tyrosine kinase receptor), shares several downstream pathways with EGFR, including RAS/RAF/MAPK and PI3K/AKT signaling pathways [173,183].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“MET activation, by either gene amplification or ligand stimulation, accounts for 5–10% of lung cancer resistance to EGFR TKIs [12,14].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [14]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23]. In our cohort, it was identified in T790M-preserved (5/19) and T790M-loss (1/21) cases, and the second most common resistance mechanism after EGFR tertiary mutations (5/42, 14%).”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,228
Self-citationEscape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 824
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G. D., Joensuu, H., Roberts, P. J., Eisenberg, B. L., von Mehren, M., Fletcher, C. D. M., Sandau, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2265 · Cited by 814
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Research works printed but not linked: 2
- J. G. Christensen et al., Cancer Res.63, 7345 (2003).
- F. M. Yakes et al., Cancer Res.62, 4132 (2002).
Cited by
Items 901–1,000 of 1,038
Laurie, S. A., & Goss, G. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4522 · Cited by 91
Progress in cancer therapy targeting c-Met signaling pathway
Jung, K. H., Park, B. H., & Hong, S. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-0402-6 · Cited by 101
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC)
Ji, M., Guan, H., Gao, C., Shi, B., & Hou, P. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-147 · Cited by 91
Li, A., Yang, J.-J., Zhang, X.-C., Zhang, Z., Su, J., Gou, L.-Y., Bai, Y., Zhou, Q., Yang, Z., Han-Zhang, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3273 · Cited by 90
Lee, D., Yu, M., Lee, E., Kim, H., Yang, Y., Kim, K., Pannicia, C., Kurie, J. M., & Threadgill, D. W. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36435 · Cited by 91
Lee, J. J.-K., Kim, T. M., Koh, Y., Lee, S., Kim, D., Jeon, Y.-K., Chung, D. H., Yang, S.-C., Kim, Y. T., Kim, Y.-W., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.012 · Cited by 92
Johnson, M. L., Riely, G. J., Rizvi, N. A., Azzoli, C. G., Kris, M. G., Sima, C. S., Ginsberg, M. S., Pao, W., & Miller, V. A. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182161508 · Cited by 90
Madoz‐Gúrpide, J., Zazo, S., Chamizo, C., Casado, V., Caramés, C., Gavín, E., Cristóbal, I., García‐Foncillas, J., & Rojo, F. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0633-7 · Cited by 106
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Koganemaru, S., Kuboki, Y., Koga, Y., Kojima, T., Yamauchi, M., Maeda, N., Kagari, T., Hirotani, K., Yasunaga, M., Matsumura, Y., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0452 · Cited by 90
“HER3 signaling is also associated with the resistance mechanism of anti-EGFR/HER2 therapies in several malignancies (21-23).”
BackgroundGong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92
Yonesaka, K., Hirotani, K., Kawakami, H., Takeda, M., Kaneda, H., Sakai, K., Okamoto, I., Nishio, K., Janne, P. A., & Nakagawa, K. (2015) · Oncogene · doi:10.1038/onc.2015.142 · Cited by 96
Self-citationEGFR: The Paradigm of an Oncogene-Driven Lung Cancer
Riely, G. J., & Yu, H. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3154 · Cited by 93
Yamamoto, S., Tsuda, H., Miyai, K., Takano, M., Tamai, S., & Matsubara, O. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.70 · Cited by 90
Sugio, K., Uramoto, H., Onitsuka, T., Mizukami, M., Ichiki, Y., Sugaya, M., Yasuda, M., Takenoyama, M., Oyama, T., Hanagiri, T., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.09.010 · Cited by 95
Vazquez-Martin, A., Cufí, S., Oliveras-Ferraros, C., Torres-Garcia, V. Z., Corominas-Faja, B., Cuyàs, E., Bonavia, R., Visa, J., Martin-Castillo, B., Barrajón-Catalán, E., et al. (2013) · Scientific Reports · doi:10.1038/srep02560 · Cited by 90
Spigel, D. R., Edelman, M. J., Mok, T. S. K., O'Byrne, K. J., Paz-Ares, L. G., Yu, W., Rittweger, K., & Thurm, H. C. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.05.009 · Cited by 94
Self-citationStrategies for overcoming resistance to EGFR family tyrosine kinase inhibitors
Giaccone, G., & Wang, Y. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.01.003 · Cited by 89
Drug Resistance to EGFR Inhibitors in Lung Cancer
Tetsu, O., Hangauer, M. J., Phuchareon, J., Eisele, D. W., & McCormick, F. P. (2016) · Chemotherapy · doi:10.1159/000443368 · Cited by 92
Huang, Q., Wang, Q., Li, D., Xiao, W., Jia, Y., Zhang, Z., Ai, B., Cao, X., Guo, T., & Liao, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1120-4 · Cited by 97
The molecular basis of targeting protein kinases in cancer therapeutics
Tsai, C., & Nussinov, R. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.04.001 · Cited by 105
Gilmour, A. M., Abdulkhalek, S., Cheng, T. S. W., Alghamdi, F., Jayanth, P., O’Shea, L. K., Geen, O., Arvizu, L. A., & Szewczuk, M. R. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.08.008 · Cited by 89
Translating genomic information into clinical medicine: Lung cancer as a paradigm
Levy, M. A., Lovly, C. M., & Pao, W. J. (2012) · Genome Research · doi:10.1101/gr.131128.111 · Cited by 94
Cell signaling and cancer: a mechanistic insight into drug resistance
Panda, M., & Biswal, B. K. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04958-6 · Cited by 89
Watanabe, S., Sone, T., Matsui, T., Yamamura, K., Tani, M., Okazaki, A., Kurokawa, K., Tambo, Y., Takato, H., Ohkura, N., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.06.003 · Cited by 92
The dynamic nature of the kinome
Graves, L. M., Duncan, J. S., Whittle, M. C., & Johnson, G. L. (2013) · Biochemical Journal · doi:10.1042/bj20121456 · Cited by 87
Standardized decision support in next generation sequencing reports of somatic cancer variants
Dienstmann, R., Dong, F., Borger, D., Dias-Santagata, D., Ellisen, L. W., Le, L. P., & Iafrate, A. J. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.021 · Cited by 89
Understanding the colon cancer stem cells and perspectives on treatment
Garza-Treviño, E. N., Said‐Fernández, S., & Martínez-Rodríguez, H. G. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0163-7 · Cited by 104
Zucali, P. A., Ruiz, M. I. G., Giovannetti, E., Destro, A., Varella‐Garcia, M., Floor, K., Ceresoli, G. L., Rodríguez, J. A., Garassino, I. M. G., Comoglio, P. M., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn240 · Cited by 89
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
Neel, D. S., Allegakoen, D. V., Olivas, V. R., Mayekar, M. K., Hemmati, G., Chatterjee, N., Blakely, C. M., McCoach, C. E., Rotow, J. K., Le, A. T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1492 · Cited by 93
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer
Desai, A. P., Abdayem, P., Adjei, A. A., & Planchard, D. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.12.002 · Cited by 97
Yuen, H., Chan, K.-K., Grills, C., Murray, J. T., Platt-Higgins, A. M., Eldin, O. S., O'Byrne, K. J., Janne, P. A., Fennell, D. A., Johnston, P. G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2035 · Cited by 89
Self-citationAdvances in Treatment of Lung Cancer With Targeted Therapy
Cagle, P. T., & Chirieac, L. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0618-ra · Cited by 100
Kinases as targets in the treatment of solid tumors
Giamas, G., Man, Y. L., Hirner, H., Bischof, J., Kramer, K. M., Khan, K., Ahmed, S. S. L., Stebbing, J., & Knippschild, U. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.011 · Cited by 98
Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
Yoshida, T., Zhang, G., & Haura, E. B. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.014 · Cited by 97
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01714 · Cited by 88
Zhang, Y., Guessous, F., Kofman, A., Schiff, D., & Abounader, R. (2010) · PubMed · Cited by 88
Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
Goffin, J. R., & Zbuk, K. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.007 · Cited by 104
Bahcall, M., Awad, M. M., Sholl, L. M., Wilson, F. H., Xu, M., Wang, S., Palakurthi, S. S., Choi, J., Ivanova, E. V., Leonardi, G. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0876 · Cited by 98
Self-citationCapmatinib for the treatment of non-small cell lung cancer
Vansteenkiste, J., de Kerkhove, C. V., Wauters, E., & Mol, P. V. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1643239 · Cited by 99
Song, K., Minami, J. K., Huang, A. J. Y., Dehkordi, S. R., Lomeli, S. H., Luebeck, J., Goodman, M. H., Moriceau, G., Krijgsman, O., Dharanipragada, P., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0936 · Cited by 88
c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences
Viticchiè, G., & Muller, P. A. J. (2015) · Biomedicines · doi:10.3390/biomedicines3010046 · Cited by 103
Seo, B. R., Min, K.-J., Cho, I. J., Kim, S. C., & Kwon, T. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095588 · Cited by 93
Contessa, J. N., Bhojani, M. S., Freeze, H. H., Ross, B. D., Rehemtulla, A., & Lawrence, T. S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3331 · Cited by 96
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
Reguart, N., Rosell, R., Cardenal, F., Cardona, A. F., Isla, D., Palmero, R., Morán, T., Rolfo, C. D., Pallarès, M. C., Insa, A., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.02.011 · Cited by 95
Chiyomaru, T., Seki, N., Inoguchi, S., ISHIHARA, T., Mataki, H., Matsushita, R., Goto, Y., Nishikawa, R., Tatarano, S., Itesako, T., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2752 · Cited by 90
Zhou, C., & Yao, L. D. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.002 · Cited by 96
Small-Molecule Targeting of BET Proteins in Cancer
French, C. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.04.001 · Cited by 92
Grugan, K. D., Dorn, K., Jarantow, S. W., Bushey, B. S., Pardinas, J. R., Laquerre, S., Moores, S. L., & Chiu, M. L. (2017) · mAbs · doi:10.1080/19420862.2016.1249079 · Cited by 86
Tran, P. T., Fan, A. C., Bendapudi, P. K., Koh, S., Komatsubara, K., Chen, J., Horng, G., Bellovin, D. I., Giuriato, S., Wang, C. S., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002125 · Cited by 87
Lolkema, M. P., Bohets, H., Arkenau, H., Lampo, A., Barale-Thomas, E., de Jonge, M. J. A., van Doorn, L., Hellemans, P., Bono, J. S. D., & Eskens, F. A. L. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3258 · Cited by 94
Rosen, L. S., Senzer, N. N., Mekhail, T. M., Ganapathi, R. N., Chai, F., Savage, R. E., Waghorne, C. G., Abbadessa, G., Schwartz, B. E., & Dreicer, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1002 · Cited by 88
Jiao, D., Chen, J., Li, Y., Tang, X., Wang, J., Xu, W., Song, J., Li, Y., Tao, H., & Chen, Q. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13629 · Cited by 84
Stratmann, A. T., Fecher, D., Wangorsch, G., Göttlich, C., Walles, T., Walles, H., Dandekar, T., Dandekar, G., & Nietzer, S. L. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.11.009 · Cited by 86
Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature
Rabinowits, G., & Haddad, R. I. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.06.016 · Cited by 89
Signal transduction therapy of cancer
Levitzki, A., & Klein, S. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.04.001 · Cited by 99
Wainberg, Z. A., Lin, L. S., DiCarlo, B. A., Dao, K. M., Patel, R., Park, D., Wang, H.-J., Elashoff, R. M., Ryba, N., & Hecht, J. R. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.280 · Cited by 89
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response
Sangodkar, J., Dhawan, N. S., Melville, H., Singh, V. J., Yuan, E., Rana, H. Q., Izadmehr, S., Farrington, C. C., Mazhar, S., Katz, S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62058 · Cited by 91
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
Politi, K., Fan, P.-D., Shen, R., Zakowski, M., & Varmus, H. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.003681 · Cited by 86
Quinn, B. J., Dallos, M., Kitagawa, H., Kunnumakkara, A. B., Memmott, R. M., Hollander, M. C., Gills, J. J., & Dennis, P. A. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0058-t · Cited by 85
“Many of these RTKs have been linked to lung tumorigenesis or have been identified as molecular targets in lung cancer, including EGFRs (29), FGFRs (30, 31), c-Met (32), and VEGFRs (33).”
BackgroundLee, Y. Y., Kim, H., Kang, M. J., Cho, B.-K., Han, S., Kim, T., & Yi, E. C. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.115 · Cited by 89
Zhou, J., Chen, X., Zhao, J., Bao, Z., Chen, X., Zhang, P., Liu, Z.-F., & Zhou, J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.010 · Cited by 86
Wu, F., Li, J., Jang, C., Wang, J., & Xiong, J. (2014) · PubMed · Cited by 91
Wu, Y.-L. L. C., Soo, R. A., Locatelli, G., Stammberger, U. M., Scagliotti, G. V., & Park, K. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.003 · Cited by 85
Glycosylation Alterations in Lung and Brain Cancer
Lemjabbar‐Alaoui, H., McKinney, A., Yang, Y., Tran, V. M., & Phillips, J. J. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2014.11.007 · Cited by 102
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours
Janne, P. A. (2008) · Lung Cancer · doi:10.1016/s0169-5002(08)70099-0 · Cited by 92
Self-citationEvolution of resistance to anti-cancer therapy during general dosing schedules
Foo, J., & Michor, F. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.11.022 · Cited by 86
Zhou, Y., Rideout, W. M., Zi, T., Bressel, A., Reddypalli, S., Rancourt, R. C., Woo, J.-K., Horner, J. W., Chin, L., Chiu, M. I., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1595 · Cited by 88
Gastric cancer and the epoch of immunotherapy approaches
Niccolai, E., Taddei, A., Prisco, D., & Amedei, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i19.5778 · Cited by 88
Juchum, M., Günther, M., Döring, E., Sievers‐Engler, A., Lämmerhofer, M., & Laufer, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00178 · Cited by 86
The promise of anti-ErbB3 monoclonals as new cancer therapeutics
Aurisicchio, L., Marra, E., Roscilli, G., Mancini, R., & Ciliberto, G. (2012) · Oncotarget · doi:10.18632/oncotarget.550 · Cited by 86
Paller, C. J., Bradbury, P. A., Ivy, S. P., Seymour, L., LoRusso, P. M., Baker, L., Rubinstein, L., Huang, E., Collyar, D., Groshen, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0521 · Cited by 84
The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells
Mumenthaler, S. M., Foo, J., Choi, N. C., Heise, N., Leder, K., Agus, D. B., Pao, W. J., Michor, F., & Mallick, P. (2015) · Cancer Informatics · doi:10.4137/cin.s19338 · Cited by 95
Gainor, J. F., Niederst, M. J., Lennerz, J. K., Dagogo‐Jack, I., Stevens, S. E., Shaw, A. T., Sequist, L. V. D., & Engelman, J. A. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.02.021 · Cited by 84
Self-citationU3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
Haratani, K., Yonesaka, K., Takamura, S., Maenishi, O., Kato, R., Takegawa, N., Kawakami, H., Tanaka, K., Hayashi, H., Takeda, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126598 · Cited by 85
2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations
Trzaska, C., Amand, S., Maulay-Bailly, C., Leroy, C., Marchand, V., Duvernois‐Berthet, E., Saliou, J., Benhabiles, H., Werkmeister, E., Chassat, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15140-z · Cited by 99
A Live-Cell Screen for Altered Erk Dynamics Reveals Principles of Proliferative Control
Goglia, A. G., Wilson, M. Z., Jena, S. G., Silbert, J., Basta, L. P., Devenport, D., & Toettcher, J. E. (2020) · Cell Systems · doi:10.1016/j.cels.2020.02.005 · Cited by 89
Huang, X., Li, E., Shen, H., Wang, X., Tang, T., Zhang, X., Xu, J., Tang, Z., Guo, C., Bai, X., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00152 · Cited by 83
Histone methyltransferase and drug resistance in cancers
Yang, C., Zhang, J., Ma, Y., Wu, C., Cui, W., & Wang, L. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01682-z · Cited by 90
Guo, Y., Song, J., Wang, Y., Huang, L., Sun, L., Zhao, J., Zhang, S., Jing, W., Ma, J., & Han, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.610923 · Cited by 95
Haikala, H. M., Lopez, T., Köhler, J., Eser, P. O., Xu, M., Zeng, Q., Teceno, T. J., Ngo, K., Zhao, Y., Ivanova, E. V., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2426 · Cited by 89
Self-citationMechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 116
Bilodeau, M. T., Balitza, A. E., HOFFMAN, J. M. J., Manley, P. J., Barnett, S. F., Defeo-Jones, D., Haskell, K., Jones, R. E., Leander, K. R., Robinson, R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.074 · Cited by 83
Wang, W., Li, Q., Takeuchi, S., Yamada, T., Koizumi, H., Nakamura, T., Matsumoto, K., Mukaida, N., Nishioka, Y., Sone, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1171 · Cited by 92
Advances in Target Therapy for Lung Cancer
Mitsudomi, T. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp174 · Cited by 95
Self-citationDisease-associated glycans on cell surface proteins
Takahashi, M., Kizuka, Y., Ohtsubo, K., Gu, J., & Taniguchi, N. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.04.008 · Cited by 91
Pan, B., Chan, G. K. Y., Chénard, M., Chi, A., Davis, L. J., Deshmukh, S. V., Gibbs, W. W., Gil, S., Hang, G., Hatch, H., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2541 · Cited by 91
Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs
Pennacchietti, S., Cazzanti, M., Bertotti, A., Rideout, W. M., Han, M., Gyuris, J., Perera, T. P. S., Comoglio, P. M., Trusolino, L., & Michieli, P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0761 · Cited by 82
Amplification of chromosomal segment 4q12 in non-small cell lung cancer
Ramos, A. H., Dutt, A., Mermel, C., Perner, S., Cho, J., LaFargue, C. J., Johnson, L. A., Stiedl, A.-C., Tanaka, K. E., Bass, A., et al. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.21.9764 · Cited by 83
Self-citationInsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Ma, Y., Tang, N., Thompson, R. C., Mobley, B. C., Clark, S. W., Sarkaria, J. N., & Wang, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1677 · Cited by 87
MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING
Zhang, Y., Yang, Q., Zeng, X., Wang, M., Dong, S., Yang, B., Tu, X., Wei, T., Xie, W., Zhang, C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1500 · Cited by 86
Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations
Yeo, W.-L., Riely, G. J., Yeap, B. Y., Lau, M. W., Warner, J. L., Bodio, K., Huberman, M. S., Kris, M. G., Tenen, D. G., Pao, W., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181dd1386 · Cited by 83
Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma
Uramoto, H., Shimokawa, H., Hanagiri, T., Kuwano, M., & Ono, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.008 · Cited by 88
Onitsuka, T., Uramoto, H., Ono, K., Takenoyama, M., Hanagiri, T., Oyama, T., Izumi, H., Kohno, K., & Yasumoto, K. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d0a4db · Cited by 87
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells
Kawaguchi, K., Murakami, H., Taniguchi, T., Fujii, M., Kawata, S., Fukui, T., Kondo, Y., Osada, H., Usami, N., Yokoi, K., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp097 · Cited by 88
Watermann, I., Schmitt, B., Stellmacher, F., Müller, J., Gaber, R., Kugler, C., Reinmuth, N., Huber, R. M., Thomas, M., Zabel, P., et al. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0362-5 · Cited by 86
Hamburger, A. W. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9077-5 · Cited by 90
The Inflammatory Tumor Microenvironment, Epithelial Mesenchymal Transition and Lung Carcinogenesis
Heinrich, E. L., Walser, T. C., Krysan, K., Liclican, E. L., Grant, J. L., Rodriguez, N., & Dubinett, S. M. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0089-0 · Cited by 98
Fan, W., Tang, Z., Yin, L., Morrison, B., Hafez-Khayyata, S., Fu, P., Huang, H., Bagai, R., Jiang, S., Kresak, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2668 · Cited by 83
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
Cadranel, J. L., Ruppert, A.-M., Beau‐Faller, M., & Wislez, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.009 · Cited by 89
Metadata
- Authors
- Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., & Jänne, P. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
- ORCID
- Venue
- Science
- Published
- 2007-05-18
- Volume
- 316
- Issue
- 5827
- Pages
- 1039-1043
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1998971866
- Cited by
- 4,496
- References
- 22
- Citations by year
- 2026: 97 · 2025: 109 · 2024: 123 · 2023: 136 · 2022: 152 · 2021: 191 · 2020: 182 · 2019: 214 · 2018: 269 · 2017: 288 · 2016: 291 · 2015: 375 · 2014: 349 · 2013: 369 · 2012: 345
- FWCI
- 207.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca111560-05)
- National Cancer Institute (R01-CA111560, P01CA089021, R01CA114465, P20CA090578, P20 CA 90578-02, 1K12CA87723-01, K08CA120060, K12CA087723)
- National Institute of General Medical Sciences (GM 41890, R01GM041890)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- MET amplification, gefitinib resistance, lung cancer, HER3, PI3K signaling, EGFR kinase inhibitors, erlotinib, drug resistance, ErbB receptors, MET oncogene
- MeSH terms
- Gefitinib, Proto-Oncogene Mas, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cricetulus, Enzyme Inhibitors, Gene Amplification, Cricetinae, Humans, Indoles, Lung Neoplasms, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Sulfones, Signal Transduction, CHO Cells, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Phosphatidylinositol 3-Kinases, Receptor, ErbB-3, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.